Scholar 1 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Little rockUnited statesUniversity of arkansasAakash mukherjeeDepartment of internal medicineCollege of medicineWinthropp rockefeller cancer instituteWinthropp rockefeller cancer institute transplant centerCancer institute transplant centerCancer instituteMedical sciencesInternal medicineContributing kiteRelapsed refractoryb cell lymphomaPatients with relapsed refractory diffuse largeb cell lymphomaScholar 1 study